Zoetis (ZTS) Q4 2025: Semperica Trio Hits $1B U.S. Milestone Amid 12% Franchise Growth
Zoetis navigated a dynamic 2025 with disciplined execution, as its Semperica franchise achieved double-digit growth and the flagship Trio product surpassed $1 billion in U.S. sales, offsetting U.S. macro and competitive pressures. Strategic portfolio balance, international expansion, and robust pipeline momentum position Zoetis for continued resilience and measured growth in 2026, even as guidance reflects a moderation from historical highs. Investors should watch for competitive intensity in key categories and the impact of evolving pet care economics on U.S. demand and pricing power.
Summary
- Semperica Franchise Expansion: Trio’s $1B U.S. milestone and 12% franchise growth anchor Zoetis’ leadership in parasiticides.
- Operational Resilience: Broad-based international and livestock growth offset U.S. headwinds and OA pain softness.
- Guidance Moderation: 2026 outlook reflects prudent assumptions amid macro and competitive crosscurrents.
Business Overview
Zoetis is a global leader in animal health, providing medicines, vaccines, diagnostics, and services for both companion animals (pets) and livestock. The company generates revenue primarily through its two reportable segments: Companion Animal (canine, feline, diagnostics, and pain management therapeutics) and Livestock (cattle, swine, poultry, aquaculture). Its business model leverages a diverse portfolio, global commercial reach, and ongoing innovation to drive growth across veterinary and retail channels.
Performance Analysis
Zoetis delivered 6% organic operational revenue growth and 7% adjusted net income growth for 2025, in line with expectations and supported by strong international and livestock segment performance. International markets grew 8% organically, while the U.S. delivered 4% organic growth, demonstrating the value of Zoetis’ geographic diversification. The Semperica franchise, parasiticide portfolio, was the standout, growing 12% operationally with Trio driving 13% growth and surpassing $1 billion in U.S. sales, solidifying its status as the leading canine parasiticide globally.
Companion animal diagnostics grew 13% operationally, buoyed by new product launches like VetScan OptiCell and AI-enabled platform enhancements. Livestock posted 8% organic growth, with poultry and aquaculture delivering double-digit gains, benefiting from focused execution post-MFA divestiture and global protein demand tailwinds. However, the OA pain franchise declined 3% operationally, with U.S. OA pain down 12%, reflecting both market and product-specific challenges. The dermatology franchise grew 6% operationally for the year but slowed to 1% in Q4 amid heightened competition and promotional activity.
- Parasiticide Leadership: Semperica Trio’s $1B U.S. sales and global share gains underscore sustained demand and channel strength.
- Diagnostics Momentum: 13% operational growth in diagnostics highlights successful innovation and portfolio balance.
- OA Pain Weakness: OA franchise softness, especially in the U.S., remains a drag, though new launches and education efforts aim to stabilize trends.
Gross margin expansion benefited from portfolio mix and price, partially offset by manufacturing cost pressures. Cost discipline and capital returns remained priorities, with over $3.2 billion in buybacks and $800 million in dividends supporting shareholder value.
Executive Commentary
"Our execution further strengthened the foundation for what's next, from advancing long-acting approvals and a robust pipeline that extends our growth runway, to strategic actions that sustain growth through competition, to sharpening focus in livestock post-MFA, and strengthening our commercial and medical capabilities globally."
Kristin Peck, Chief Executive Officer
"Our full year results reflect our ability to grow even in an increasingly competitive environment through the diversity of our portfolio, strength of our commercial relationships, and the value our products provide to our customers."
Whitney Joseph, Chief Financial Officer
Strategic Positioning
1. Franchise Leadership in Parasiticides and Diagnostics
Zoetis’ Semperica franchise, including Trio, continues to set the standard in canine parasiticides, leveraging first-mover advantage and omni-channel access to maintain share and compliance. Diagnostics innovation, such as VetScan OptiCell and AI-enabled platforms, strengthens cross-portfolio synergies and drives incremental growth.
2. Portfolio Balance and International Diversification
International markets and livestock segments provided essential ballast against U.S. macro and competitive headwinds. Broad-based livestock growth, especially in poultry, cattle, and aquaculture, highlights execution strength and the benefits of geographic and species diversification.
3. Navigating U.S. Macro and Competitive Pressures
U.S. companion animal performance faced headwinds from price-sensitive pet owners, reduced routine care visits, and aggressive competitive promotions, particularly in dermatology and OA pain. Zoetis is responding with targeted channel optimization, education, and direct-to-consumer investment, but near-term growth is expected to remain moderate.
4. Innovation Pipeline and Lifecycle Management
Pipeline momentum remains robust, with 12 potential blockbusters in development and launches of long-acting OA pain products (Lanivia, Portela) expected to drive future growth. Strategic lifecycle management and patent protection (e.g., Apoquel through 2032) support durable competitive advantages.
5. Cost Discipline, Capital Allocation, and ERP Modernization
Cost management and capital discipline continue to underpin Zoetis’ financial strategy, with ongoing investments in ERP modernization to enhance global reporting, productivity, and operational agility. The recent convertible bond offering funded significant buybacks without compromising investment capacity.
Key Considerations
Zoetis enters 2026 with a balanced portfolio and a measured growth outlook, reflecting both internal execution and external realities. The following considerations are central to assessing the company’s forward trajectory:
- Competitive Intensity in Key Categories: Dermatology and parasiticide segments are seeing new entrants and aggressive promotions, pressuring share and pricing.
- U.S. Pet Owner Price Sensitivity: Clinic traffic for routine care remains subdued as pet owners react to cumulative price increases, driving clinics to reassess cost structures and value delivery.
- International and Livestock Offsets: Strong growth in international and livestock segments is critical for overall resilience and margin stability.
- OA Pain Franchise Recovery: New product launches and educational outreach are necessary to stabilize and eventually return the OA pain portfolio to growth.
- Pipeline Execution and Launch Timing: The timing and uptake of new innovations, especially long-acting OA pain therapies, will shape medium-term growth potential.
Risks
Zoetis faces ongoing risks from competitive launches, especially in dermatology and parasiticides, and from macro factors impacting U.S. pet owner spending. Aggressive pricing and promotional activity could erode franchise share and margin, while OA pain franchise recovery remains uncertain. Accounting adjustments related to ERP and fiscal year alignment introduce additional complexity to reported results and comparability. Regulatory delays or adverse events for new products could also impact future growth.
Forward Outlook
For 2026, Zoetis guided to:
- 3% to 5% organic operational revenue growth
- 3% to 6% organic operational growth in adjusted net income
For full-year 2026, management expects:
- Reported revenue of $9.825 to $10.025 billion
- Adjusted diluted EPS of $7.00 to $7.10
Management highlighted:
- Key growth drivers remain Semperica franchise and diagnostics, with livestock also contributing meaningfully.
- Competitive and macro headwinds are expected to moderate as the year progresses, but Q1 and Q2 will lap tougher comps.
Takeaways
Zoetis delivered resilient growth in 2025, driven by franchise leadership and international momentum, but faces a more competitive and price-sensitive U.S. environment in 2026. Investors should monitor the interplay of innovation launches, competitive dynamics, and pet care macro trends for signs of upside or incremental risk.
- Franchise Durability: Semperica and diagnostics outperformed, validating the portfolio’s innovation-led growth model.
- Competitive and Macro Pressures: Dermatology and OA pain face persistent headwinds, with U.S. consumer price sensitivity a key watchpoint.
- Pipeline and Portfolio Management: 2026 is a transition year, with medium-term upside tied to new product launches and operational execution.
Conclusion
Zoetis enters 2026 with a strong foundation and diversified growth engines, but faces a more challenging U.S. landscape and competitive environment. The company’s ability to execute on innovation, manage channel dynamics, and deliver on pipeline promises will determine whether it can reaccelerate growth beyond the current guidance band.
Industry Read-Through
Zoetis’ results highlight broad themes in animal health: macro-driven pet owner price sensitivity is pressuring routine care and shifting demand toward value and convenience, while innovation and lifecycle management are critical to defending share in crowded categories. International and production animal markets remain reliable growth engines for diversified players. Competitors in animal health and adjacent sectors should expect continued channel evolution, aggressive promotional tactics, and a premium on differentiated portfolios and global execution. The pace of innovation adoption and the ability to navigate pricing and regulatory complexity will separate leaders from laggards as the industry adapts to new market realities.